saypha ChiQ
Croma-Pharma GmbH · Decision date Oct 8, 2026
What did the FDA approve?
FDA approved the post-approval study (PAS) protocol for the saypha® ChiQ™ dermal implant, supplement S002 to PMA P250021. The decision, dated 2026-10-08, is recorded as an approval under the Normal 180 Day Track with no user fee.
The PAS protocol was submitted to satisfy conditions of approval in the original P250021 approval order. The source statement does not describe the study design, endpoints, enrollment, or timeline. The device is categorized as an implant, dermal, for aesthetic use under product code LMH, with Croma-Pharma GmbH as the applicant.
FDA approval order statement
Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250021.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 8, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250021/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Croma-Pharma GmbH
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Oct 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Croma-Pharma GmbH
- Product code
- LMH
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250021. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250021 · Original PMA
saypha ChiQ
P250021/S002 received
Application receipt date recorded by FDA.
P250021/S001 · Related supplement
saypha ChiQ
P250021/S002 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P250021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
saypha ChiQP250021 | Croma-Pharma GmbH | PMA approval | Jun 12, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
Restylane ContourP140029/S058 | Q-Med AB | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Croma-Pharma GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Industriezeile 6, Leobendorf, 2100
Sources and methodology
- Original FDA record: P250021/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



